STIM Narrows Losses as Greenbrook Clinics Drive Revenue Growth and Margin Improvement
Market Chameleon (Tue, 11-Aug 6:30 AM ET)
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Globe Newswire (Tue, 11-Aug 7:50 AM ET)
Neuronetics and Jorey Chernett Announce Shared Vision
Globe Newswire (Mon, 3-Aug 8:00 AM ET)
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 31-Jul 5:00 PM ET)
Globe Newswire (Tue, 28-Jul 8:32 AM ET)
Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
Globe Newswire (Tue, 28-Jul 8:30 AM ET)
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
Globe Newswire (Mon, 20-Jul 4:05 PM ET)
Globe Newswire (Mon, 6-Jul 8:30 AM ET)
Neuronetics Appoints Robert Greene as Senior Vice President Sales
Globe Newswire (Tue, 2-Jun 4:30 PM ET)
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
Globe Newswire (Tue, 2-Jun 8:32 AM ET)
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Neuronetics trades on the NASDAQ stock market under the symbol STIM.
As of August 28, 2026, STIM stock price declined to $2.93 with 311,084 million shares trading.
STIM has a beta of 2.93, meaning it tends to be more sensitive to market movements. STIM has a correlation of 0.11 to the broad based SPY ETF.
STIM has a market cap of $223.26 million. This is considered a Small Cap stock.
Last quarter Neuronetics reported $42 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.07.
In the last 3 years, STIM traded as high as $5.92 and as low as $.52.
The top ETF exchange traded funds that STIM belongs to (by Net Assets): PSIL, VTI, VXF, IWC, QQQS.
STIM has underperformed the market in the last year with a price return of -12.8% while the SPY ETF gained +20.7%. However, in the short term, STIM had mixed performance relative to the market. It has outperformed in the last 3 months, returning +140.2% vs +3.2% return in SPY. But in the last 2 weeks, STIM shares have been beat by the market, returning -3.3% compared to an SPY return of -0.6%.
STIM support price is $2.81 and resistance is $3.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STIM shares will trade within this expected range on the day.
